RE: Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP)21 Nov 2022 23:04
Given that Tamiflu and Baloxivir are already approved flu therapeutics ( Tamiflu since 1999 and Baloxivir since 2018) is it not possible that this study's entire aim is to assess existing flu drugs with Dexamethasone - given its success in Covid ?
Corticosteroids have been trialed unsuccessfully for Flu many times before and are proven to be dangerous to flu sufferers, but there is evidence that Dexa works better with Remdesevir in C-19, so maybe they're going after Dexa again as a combination therapy for Flu.
"In hospitalized patients with COVID-19 pneumonia receiving low-flow oxygen and dexamethasone, the addition of remdesivir was not associated with shorter hospitalization or lower in-hospital mortality but may have reduced the combined outcome of death and transfer to the intensive care unit."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853490/
And here's the prevailing evidence against Corticosteroids for Flu.
" Due to high morbidity and mortality, corticosteroids were seen as potential co-adjuvants in patients with influenza, especially those with the most severe forms. Animal studies suggested that the use of corticosteroids could ameliorate lung lesion in infected mice and improved survival induced by influenza A (H1N1pdm09) virus [32]. Due to this potential mechanism, the use of steroids has been seen as a potential alternative to stop disease progression and improve clinical outcomes.
The first multicentric observational study was published in 2011 under the European Society of Intensive Care Medicine H1N1 registry. It included 220 patients in ICUs around the globe. One of the most surprising findings was that the use of corticosteroids was as high as 60% and the use of corticosteroids was found not to be improving ICU mortality and was associated with increased risk of hospital-acquired pneumonia [33]. After this study, others were published showing the same results in patients with influenza A (H1N1pdm09) in Korea [34], France [35] and Canada [36] and with influenza A (H7N9) viral pneumonia in China [37]. After these studies, there was a good body of evidence against the routine use of steroids in patients with influenza. More recently, a large cohort study of critically ill patients admitted to ICUs in Spain found that the use of steroids was still prevalent and being prescribed in approximately one-third of the patients admitted to the 148 ICUs in the study. The relevance of this observational study is that it found that the use of corticosteroids was associated to an increased ICU mortality by a propensity score matching and competing risks analysis [38]. "
From
Corticosteroids for CAP, influenza and COVID-19: when, how and benefits or harm?
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877325/
Obviously I may be off on completely the wrong tangent again, but it's a reasonable question to ask why Dexamethasone is on there ( with such strong evidence against CSs for flu )with 2 long established and proven